Dupont Capital Management Corp Intercept Pharmaceuticals, Inc. Transaction History

Dupont Capital Management Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$11.23 - $19.59 $188,776 - $329,307	-16,810 Reduced 59.44%	11,469 $158,000
Q1 2022 Apr 27, 2022	SELL	$13.37 - $17.79 $33,438 - $44,492	-2,501 Reduced 8.13%	28,279 $460,000
Q4 2021 Jan 31, 2022	BUY	$14.28 - $19.53 $140,600 - $192,292	9,846 Added 47.03%	30,780 $501,000
Q3 2021 Nov 03, 2021	SELL	$12.99 - $20.47 $38,450 - $60,591	-2,960 Reduced 12.39%	20,934 $311,000
Q1 2021 Apr 29, 2021	BUY	$19.33 - $37.75 $313,358 - $611,965	16,211 Added 211.0%	23,894 $551,000

Q4 2020 Jan 28, 2021	SELL	$24.48 - $42.47 $14,051 - $24,377	-574 Reduced 6.95%	7,683 $190,000
Q3 2020 Oct 29, 2020	BUY	$39.09 - $53.44 $101,164 - $138,302	2,588 Added 45.65%	8,257 $342,000
Q2 2020 Jul 24, 2020	BUY	$46.7 - $92.04 $101,105 - $199,266	2,165 Added 61.79%	5,669 $272,000
Q1 2020 Apr 29, 2020	BUY	$48.35 - $118.68 $169,418 - $415,854	3,504 New	3,504 $221,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.